Intravenous Infusions is trading at GHS 0.54, down 5.26%, with no clear company-specific catalyst identified.

  • On October 26, the company discussed plans to improve production, revenue and profitability in 2027, following steps to address working-capital constraints. The update does not establish a cause for the share-price move.
  • The Ghana Stock Exchange Composite Index rose on October 27, so available evidence does not indicate a broad-market decline explaining the move.